Drew Weissman

Drew Weissman
John Sears · CC BY-SA 4.0 · source
Name	Drew Weissman
Birth date	1959
Birth place	Lexington, Massachusetts
Nationality	American
Fields	Immunology, Molecular Biology, Virology
Institutions	University of Pennsylvania, Children's Hospital of Philadelphia
Alma mater	Brandeis University, Boston University School of Medicine
Known for	mRNA vaccine modification, RNA immunology
Awards	Nobel Prize in Physiology or Medicine, Lasker~DeBakey Clinical Medical Research Award

Drew Weissman Drew Weissman is an American physician-scientist and immunologist known for foundational work on modified messenger RNA that enabled rapid development of vaccines. His research at the University of Pennsylvania and collaborations with biotechnology companies helped transform vaccine technology, influencing responses to the COVID-19 pandemic and advancing applications in infectious disease, oncology, and therapeutics. Weissman’s work has been recognized by major scientific awards and global institutions.

Early life and education

Weissman was born in Lexington, Massachusetts and raised in a family connected to the Boston area, attending primary and secondary schools near Boston, Massachusetts and Cambridge, Massachusetts. He earned a Bachelor of Science at Brandeis University before attending Boston University School of Medicine for his MD and PhD, where he trained in immunology and clinical medicine alongside faculties affiliated with Beth Israel Deaconess Medical Center and Massachusetts General Hospital. Weissman completed clinical training and research fellowships that connected him to networks at National Institutes of Health and academic centers such as University of Pennsylvania and Children's Hospital of Philadelphia, establishing collaborations with researchers linked to institutions including Harvard University and Yale University.

Research and career

Weissman’s early career combined clinical practice with basic research in RNA biology, innate immunity, and vaccine immunology at laboratories associated with National Institute of Allergy and Infectious Diseases, National Institutes of Health, and academic departments at the Perelman School of Medicine at the University of Pennsylvania. He established a laboratory that investigated interactions among nucleic acids, pattern recognition receptors such as Toll-like receptor 7 and Toll-like receptor 8, and dendritic cell activation studied in contexts like HIV/AIDS and influenza. Weissman collaborated with colleagues experienced in lipid nanoparticle delivery from industry partners including Moderna, Pfizer, and startup groups spun out of BioNTech-related research, while engaging with translational programs coordinated with Food and Drug Administration-related regulatory science and clinical trial networks such as National Institutes of Health Clinical Center consortia. His work involved techniques and concepts associated with messenger RNA, nucleoside modification, and delivery platforms influenced by research at institutions like Massachusetts Institute of Technology and Stanford University.

mRNA vaccine development and impact

Weissman and his collaborator discovered that incorporating modified nucleosides such as pseudouridine into synthetic messenger RNA reduced innate immune sensing and increased translational efficiency, a finding that connected to basic research on RNA interference, toll-like receptors, and pattern recognition receptors studied across laboratories at Rockefeller University and Scripps Research. This biochemical innovation enabled development of lipid nanoparticle-formulated mRNA vaccines that were rapidly advanced through preclinical studies and clinical trials by companies including Moderna, BioNTech, and Pfizer during the COVID-19 pandemic response to SARS-CoV-2. The technology underpinned emergency use authorizations and regulatory approvals overseen by agencies such as the Food and Drug Administration and European Medicines Agency, altering vaccine deployment strategies used in public health programs led by World Health Organization and national ministries like the United States Department of Health and Human Services. Beyond COVID-19, Weissman’s contributions influenced mRNA approaches for influenza vaccine development, personalized cancer vaccines trialed at centers like Memorial Sloan Kettering Cancer Center, and platforms explored for Zika virus and Ebola virus by consortiums involving Centers for Disease Control and Prevention and global research networks.

Awards and honors

Weissman has received major recognitions from bodies including the Nobel Prize in Physiology or Medicine alongside a collaborator for discoveries enabling mRNA therapeutics; prestigious prizes such as the Albert Lasker Award for Clinical Medical Research and the Canada Gairdner International Award; memberships in bodies like the National Academy of Sciences and the American Academy of Arts and Sciences; and honors from organizations including the Royal Society and the Breakthrough Prize in Life Sciences. He has been awarded institutional prizes and lectureships connected to universities such as Harvard Medical School, Yale School of Medicine, Columbia University, and foundations including the Gordon and Betty Moore Foundation and the Howard Hughes Medical Institute.

Personal life and legacy

Weissman’s personal biography includes residence and academic appointment in Philadelphia, Pennsylvania and involvement with translational programs at Children's Hospital of Philadelphia and the Perelman School of Medicine. His legacy is reflected in industrial collaborations with biotechnology firms like Moderna and BioNTech, policy discussions involving agencies such as the Centers for Disease Control and Prevention and science advisory groups to governments including the United States and multinational initiatives led by the World Health Organization. His scientific lineage connects to trainees and collaborators now at institutions such as Stanford University School of Medicine, University of California, San Francisco, and Johns Hopkins University, shaping ongoing research in RNA therapeutics, vaccine design, and global health responses exemplified by programs at Gavi, the Vaccine Alliance and international consortia funded by entities like the Bill & Melinda Gates Foundation.

Category:American immunologists Category:Recipients of the Nobel Prize in Physiology or Medicine